Notch signaling triggers the tumor heterogeneity of small cell lung cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. Combined small cell lung cancer: current progress and unmet needs.American journal of cancer research · 2023
   Review
2. Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities.ESMO open · 2022
   Article
3. Molecular profiles of small cell lung cancer subtypes: therapeutic implications.Molecular therapy oncolytics · 2021
   Review
4. Notch pathway in small-cell lung cancer: from preclinical evidence to therapeutic challenges.Cellular oncology (Dordrecht, Netherlands) · 2019
   Review
5. Elevated Notch1 enhances interleukin-22 production by CD4Bioscience reports · 2018
   Article

Corrections and comments

• Comment on
  Intratumoural heterogeneity generated by Notch signalling promotes small-cell lung cancer.2017

Authors and funding

3 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.